The purpose of this study was to determine the prevalence of multiple sclerosis (MS) in Australia in 2010 using a novel method based on Australia-wide prescription data for MS-specific disease modifying agents. The results obtained were validated against two other prevalence estimates.
Methods:
We obtained the total number of scripts for medications that were used exclusively for the treatment of MS written in Australia for the period January–December 2010. The percentage of MS patients using medications (42–55%) was taken from state-specific surveys of MS Society clients. To estimate prevalence we divided the annual number of scripts dispensed by 12 and adjusted for penetration of medications by state.
Results:
The prevalence of MS in Australia in 2010 calculated using the prescription method was 21,283 people (95.5/100,000). This compared to 21,200 people (95.2/100,000) obtained from the Australian Bureau of Statistics (ABS) Survey of Disability, Ageing and Carers (SDAC) survey of 2009 and 20,471 people (91.9/100,000) using MS Society client numbers. Prevalence increased with increasing latitude, with the prevalence for Tasmania over seven times that of the Northern Territory. Results were sensitive to the percentage of people with MS being treated.
Conclusions:
Calculation of prevalence of MS using nation-wide prescription data is a novel method that generates results similar to other potentially more resource-intensive methods.
PalmerAJColmanSO’LearyBThe Economic Impact of Multiple Sclerosis in Australia in 2010. Mult Scler2013. [in press].
3.
SimpsonSJrBlizzardLOtahalP. Latitude is significantly associated with the prevalence of multiple sclerosis: A meta-analysis. J Neurol Neurosurg Psychiatry2011; 82: 1132–1141.
4.
BeretichBBeretichTExplaining multiple sclerosis prevalence by ultraviolet exposure: A geospatial analysis. Mult Scler2009; 15: 891–898.
5.
McCallMGBreretonTLDawsonA. Frequency of multiple sclerosis in three Australian cities - Perth, Newcastle, and Hobart. J Neurol Neurosurg Psychiatry1968; 31: 1–9.
6.
HammondSRMcLeodJGMillingenKS. The epidemiology of multiple sclerosis in three Australian cities: Perth, Newcastle and Hobart. Brain1988; 111: 1–25.
7.
McLeodJGHammondSRHallpikeJFEpidemiology of multiple sclerosis in Australia - NSW and SA survey results. Med J Aust1994; 160. Med J Aust. 1994 Feb 7; 160 (3): 117–22.
8.
BarnettMHWilliamsDBDayS. Progressive increase in incidence and prevalence of multiple sclerosis in Newcastle, Australia: A 35-year study. J Neurol Sci2003; 213: 1–6.
9.
SimpsonSLJrPittasFvan der MeiI. Trends in the epidemiology of multiple sclerosis in Greater Hobart, Tasmania: 1951 to 2009. J Neurol Neurosurg Psychiatry2011; 82: 180–187.
10.
PoserCMHibberdPLBenedikzJ. Analysis of the ‘epidemic’ of multiple sclerosis in the Faroe Islands. I. Clinical and epidemiological aspects. Neuroepidemiology1988; 7: 168–180.
11.
BentzenJMeulengracht FlachsEStenagerE. Prevalence of multiple sclerosis in Denmark 1950–2005. Mult Scler2010; 16: 520–525.
12.
MarrieRAYuNBlanchardJLeungS. The rising prevalence and changing age distribution of multiple sclerosis in Manitoba. Neurology2010; 74: 465–471.
13.
HawkesCHRamkumarNBakerR. Multiple sclerosis in Latter Day Saints (Mormons). Acta Neurol Scand2007; 115: 260–264.
14.
VukusicSVan BockstaelVGosselinS. Regional variations in the prevalence of multiple sclerosis in French farmers. J Neurol Neurosurg Psychiatry2007; 78: 707–709.
15.
KurtzkeJFBeebeGWNormanJEJrEpidemiology of multiple sclerosis in U.S. veterans: 1. Race, sex, and geographic distribution. Neurology1979; 29: 1228–1235.
16.
BaumhacklUEiblGGanzingerU. Prevalence of multiple sclerosis in Austria. Results of a nationwide survey. Neuroepidemiology2002; 21: 226–234.
17.
BaumHMRothschildBBThe incidence and prevalence of reported multiple sclerosis. Ann Neurol1981; 10: 420–428.
18.
KurtzkeJFDelasnerie-LaupretreNWallinMTMultiple sclerosis in North African migrants to France. Acta Neurol Scand1998; 98: 302–309.
McLeodJGHammondSRHallpikeJFEpidemiology of multiple sclerosis in Australia. With NSW and SA survey results. Med J Aust1994; 160: 117–122.
25.
TremlettHVan der MeiIPittasF. Adherence to the immunomodulatory drugs for multiple sclerosis: Contrasting factors affect stopping drug and missing doses. Pharmacoepidemiol Drug Saf2008; 17: 565–576.
BarnettMHWilliamsDBDayS. Progressive increase in incidence and prevalence of multiple sclerosis in Newcastle, Australia: A 35-year study. J Neurol Sci2003; 213: 1–6.
30.
SimmonsRDHallCAGleesonP. Prevalence survey of multiple sclerosis in the Australian Capital Territory. Intern Med J2001; 31: 161–167.
31.
FromontABinquetCSauleauEA. Geographic variations of multiple sclerosis in France. Brain2010; 133: 1889–1899.
32.
AhlgrenCOdenALyckeJHigh nationwide prevalence of multiple sclerosis in Sweden. Mult Scler2011; 17: 901–908.
33.
Koch-HenriksenNSorensenPSWhy does the north-south gradient of incidence of multiple sclerosis seem to have disappeared on the northern hemisphere?J Neurol Sci2011; 311: 58–63.
